Showing results (251-260 of 340) with videos related to

Sort By:
Pageof 34
Diabetes, Obesity & Metabolism|September 6, 2023
The effects of canagliflozin in type 2 diabetes in subgroups defined by population-specific body mass index: Insights from the CANVAS Program and CREDENCE trialJie Yu, Arianne N Sweeting, Chris Gianacas, et al.
The Lancet. Diabetes & Endocrinology|February 10, 2015
Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trialDick de Zeeuw, Deborah A Anzalone, Valerie A Cain, et al.
Plos One|May 15, 2015
A panel of novel biomarkers representing different disease pathways improves prediction of renal function decline in type 2 diabetesMichelle J Pena, Andreas Heinzel, Georg Heinze, et al.
Hypertension (Dallas, Tex. : 1979)|July 22, 2015
Plasma 1,25-Dihydroxyvitamin D and the Risk of Developing Hypertension: The Prevention of Renal and Vascular End-Stage Disease StudyAdriana J van Ballegooijen, Ron T Gansevoort, Hiddo J Lambers-Heerspink, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 11, 2016
Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 studyMorten Lindhardt, Frederik Persson, Petra Zürbig, et al.
Journal of the American Society of Nephrology : JASN|September 29, 2006
Renal damage after myocardial infarction is prevented by renin-angiotensin-aldosterone-system interventionWillemijn A K M Windt, Wouter B A Eijkelkamp, Robert H Henning, et al.
BMJ Open Diabetes Research & Care|December 3, 2014
Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemiaNatalie A Bello, Marc A Pfeffer, Hicham Skali, et al.
Circulation|June 27, 2018
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney FunctionBrendon L Neuen, Toshiaki Ohkuma, Bruce Neal, et al.
Kidney International|September 1, 2023
Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney diseaseKam Wa Chan, J David Smeijer, Meir Schechter, et al.
Hypertension (Dallas, Tex. : 1979)|March 17, 2010
Effect of the urotensin receptor antagonist palosuran in hypertensive patients with type 2 diabetic nephropathyLiffert Vogt, Carlos Chiurchiu, Harbajan Chadha-Boreham, et al.
Pageof 34